Activity Overview
In this video-based program, a multispecialty expert panel provides perspectives on the diagnosis and treatment of metabolic dysfunction–associated steatotic liver disease (MASLD) and its progressive subtype, metabolic dysfunction–associated steatohepatitis (MASH), which pose a critical and escalating public health crisis, particularly in patients with type 2 diabetes. The program covers recent guideline updates on these topics, appropriate management in the primary care setting, and referral to specialists in gastroenterology/hepatology.
Target Audience
This educational activity is directed toward hepatologists, gastroenterologists, endocrinologists, primary care physicians, specialty nurse practitioners, physician assistants, registered nurses, and other health care practitioners who manage MASH.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Apply evidence-based diagnostic algorithms and noninvasive testing strategies to stage fibrosis in patients with suspected metabolic dysfunction–associated steatotic liver disease (MASLD) or metabolic dysfunction–associated steatohepatitis (MASH)
- Evaluate the latest clinical trial evidence and safety considerations for new and emerging therapies in MASH
- Integrate multidisciplinary perspectives into management plans for patients with MASLD/MASH
Nancy Reau, MD
Professor of Medicine
Section Chief, Hepatology
Associate Director of Organ Transplantation
Rush University Medical Center
Chicago, IL
Advisor, Consultant, Fee-for-Service: Gilead, Ipsen, Mirum, VIR Bluejay; Grant/Research Funding: AbbVie, Bluejay, Gilead, Salix, VIR
Conan Tu, MD
Optum Medical Care
University of New York
Bethpage,
NY
Sonal Kumar, MD, MPH
Director, General Gastroenterology and Hepatology
Assistant Professor of Medicine
Weill Cornell Medical College
New York, NY
Advisor, Consultant, Fee-for-Service: Boehringer Ingelheim, Gilead Sciences, GSK, Ipsen, Madrigal, Novo Nordisk; Speakers Bureau: Boehringer Ingelheim, Gilead Sciences, GSK, Ipsen, Madrigal, Novo Nordisk; Grant/Research Funding: Gilead Sciences, GSK, Inventiva, Ipsen, Madrigal, Novo Nordisk
Conan Tu, MD, PC has no
relevant financial relationships with ineligible companies.
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
